NuVasive First-to-Market With New Spine Innovations Featured at NASS 2016
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Jefferies Reiterates Buy on NuVasive (NUVA) Following 3Q Report
October 26, 2016 8:34 AM EDTJefferies reiterated a Buy rating and $72.00 price target on NuVasive (NASDAQ: NUVA) following the company's 3Q earnings report. For the year, the company is now guiding to $952mn in sales (down from $962mn). Components of this include the US capital stocking issue of... More
